MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
1.190
+0.100
+9.17%
After Hours: 1.190 0 0.00% 16:00 03/21 EDT
OPEN
1.100
PREV CLOSE
1.090
HIGH
1.190
LOW
1.100
VOLUME
746.90K
TURNOVER
0
52 WEEK HIGH
2.650
52 WEEK LOW
1.010
MARKET CAP
196.71M
P/E (TTM)
-1.1558
1D
5D
1M
3M
1Y
5Y
SVB shock could have chilling effect on British biotech sector
Reuters · 03/13 16:26
SVB Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)
TipRanks · 03/09 04:05
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Benzinga · 03/08 00:34
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Adaptimmune Therapeutics (ADAP)
TipRanks · 03/07 09:50
Analysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Adaptimmune Therapeutics (ADAP)
TipRanks · 03/06 20:30
Adaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho Securities
TipRanks · 03/06 19:15
Why Is TCR2 Therapeutics Stock Trading Higher Today?
Benzinga · 03/06 19:01
Health Care Sector Update for 03/06/2023: BBIO, ACRS, TCRR, ADAP
NASDAQ · 03/06 18:44
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors; Tumor Infiltrating Lymphocytes (TiLs) where a patient’s own T-cells are co-administered with its next generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its clinical trials include Spearhead-1 Phase II trial with afamitres gene autoleucel; Surpass Phase I Trial with ADP-A2M4CD8, and others.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.